The ImmunoMark Summit 2026, conceptualized and curated by Convolign Business Consulting, will unite global pioneers and innovators in Immuno-Oncology (IO) and biomarker discovery, offering a strategic forum to drive the next generation of biomarkers critical to the success of IO therapies. As immunotherapies continue to reshape the landscape of cancer care, the identification and validation of robust, clinically relevant biomarkers are becoming central to the realization of precision medicine.

This two-day summit will explore cutting-edge advances in IO science, novel biomarker identification, companion diagnostics, translational research, clinical validation, and evolving regulatory frameworks. With two dedicated parallel tracks—Next-Gen Immuno-Oncology

 (NGIO) and Biomarker & Companion Diagnostics—attendees will gain deep, actionable insights, forge meaningful partnerships, and accelerate the path from discovery to delivery.

Designed to be dynamic and interactive, the event features expert-led panel discussions, real-world case studies, and one-to-one networking opportunities. Whether you're involved in academia, clinical research, pharma, diagnostics, or regulatory affairs, ImmunoMark Summit 2026 is the essential platform for stakeholders dedicated to advancing biomarker-driven solutions and transforming the future of cancer treatment.

Join us at London, UK to connect with thought leaders, gain actionable insights, and contribute to the global pioneers and innovators in Immuno-Oncology (IO) and biomarker discovery.